BioNexus Gene Lab Corp Common stock (BGLC) — Financial Flexibility Index
BioNexus Gene Lab Corp Common stock (BGLC) has a Financial Flexibility Index of -1.53x as of September 2025. Free cash flow of $-1.23 Million (operating CF $-1.23 Million minus capex $5.49K) represents -2% of total liabilities ($804.97K). Also explore BioNexus Gene Lab Corp Common stock (BGLC) equity growth momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
BioNexus Gene Lab Corp Common stock Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for BioNexus Gene Lab Corp Common stock across 9 annual periods. Check BGLC capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for BioNexus Gene Lab Corp Common stock (2016–2024)
Year-by-year free cash flow to debt coverage for BioNexus Gene Lab Corp Common stock. For the full company profile including market capitalisation, see BioNexus Gene Lab Corp Common stock stock valuation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.95x | $-2.01 Million | $-2.23 Million | $2.11 Million | ▼ -2.8% |
| 2023 | -0.93x | $-1.61 Million | $-1.76 Million | $1.74 Million | ▼ -420.9% |
| 2022 | 0.29x | $598.20K | $544.03K | $2.08 Million | ▲ +5501.6% |
| 2021 | 0.01x | $12.32K | $9.16K | $2.39 Million | ▼ -98.2% |
| 2020 | 0.28x | $974.30K | $552.68K | $3.45 Million | ▲ +115.0% |
| 2019 | -1.88x | $-204.46K | $-217.27K | $108.87K | ▼ -4.4% |
| 2018 | -1.80x | $-234.46K | $-274.08K | $130.31K | ▼ -415.4% |
| 2017 | 0.57x | $672.04K | $357.22K | $1.18 Million | ▲ +191.3% |
| 2016 | -0.62x | $-835.00 | $-835.00 | $1.34K | — |